Skip to main
CNTB

CNTB Stock Forecast & Price Target

CNTB Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Connect Biopharma Hldgs is well-positioned to capitalize on the growing demand for innovative treatments for respiratory diseases, with promising clinical data and a strong pipeline of potential therapies. However, investors should carefully monitor the progress and success of clinical trials and keep in mind the risks associated with biopharmaceutical development. Overall, the company's focus on addressing unmet needs in the respiratory market and its potential for global expansion make it a promising investment opportunity for those with a long-term outlook.

Bears say

Connect Biopharma Hldgs is a clinical-stage biotech company developing treatments for lung indications with its lead program rademikibart, an IL-4Rα inhibitor currently progressing through Phase 2 development for acute COPD and asthma. While rademikibart shows promise in its faster onset compared to Dupilumab, which is only approved for chronic use, the success of Dupilumab may be difficult to compete with given its greater clinical evidence and established relationship with Sanofi and Regeneron. Additionally, Dupilumab has been associated with risks of hyper-eosinophilia which could complicate treatment, making it a potential challenge for rademikibart to compete.

CNTB has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Connect Biopharma Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Connect Biopharma Holdings (CNTB) Forecast

Analysts have given CNTB a Strong Buy based on their latest research and market trends.

According to 3 analysts, CNTB has a Strong Buy consensus rating as of Apr 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Connect Biopharma Holdings (CNTB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.